New shot could cut heart attacks and strokes in High-Risk patients
NCT ID NCT07551492
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing an injectable drug called HRS9531 in about 9,200 people with atherosclerotic cardiovascular disease (hardened arteries). The goal is to see if it can lower the chance of major heart problems like heart attack, stroke, or death. Participants receive either the drug or a placebo shot, and the study will last until enough heart events occur to compare the groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS9531 injection
What this could lead to
If it works, this could provide a new treatment to lower the risk of major heart problems like heart attack or stroke in people with hardened arteries.
What could go wrong
This is a large Phase 3 trial, but the drug is still experimental. It may not prove effective, and side effects are possible. Results are not expected for several years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital, CAMS&PUMC
RECRUITINGBeijing, Beijing Municipality, 100037, China
Contact
Contact